Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene

Nicholas A. Olshavsky, Clay E S Comstock, Matthew J. Schiewer, Michael A. Augello, Terry Hyslop, Claudio Sette, Jinsong Zhang, Linda M. Parysek, Karen E. Knudsen

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The cyclin D1b oncogene arises from alternative splicing of the CCND1 transcript, and harbors markedly enhanced oncogenic functions not shared by full-length cyclin D1 (cyclin D1a). Recent studies showed that cyclin D1b is selectively induced in a subset of tissues as a function of tumorigenesis; however, the underlying mechanism(s) that control tumor-specific cyclin D1b induction remain unsolved. Here, we identify the RNA-binding protein ASF/SF2 as a critical, allele-specific, disease-relevant effector of cyclin D1b production. Initially, it was observed that SF2 associates with cyclin D1b mRNA (transcript-b) in minigene analyses and with endogenous transcript in prostate cancer (PCa) cells. SF2 association was altered by the CCND1 G/A870 polymorphism, which resides in the splice donor site controlling transcript-b production. This finding was significant, as the A870 allele promotes cyclin D1b in benign prostate tissue, but in primary PCa, cyclin D1b production is independent of A870 status. Data herein provide a basis for this disparity, as tumor-associated induction of SF2 predominantly results in binding to and accumulation of G870-derived transcript-b. Finally, the relevance of SF2 function was established, as SF2 strongly correlated with cyclin D1b (but not cyclin D1a) in human PCa. Together, these studies identify a novel mechanism by which cyclin D1b is induced in cancer, and reveal significant evidence of a factor that cooperates with a risk-associated polymorphism to alter cyclin D1 isoform production. Identification of SF2 as a disease-relevant effector of cyclin D1b provides a basis for future studies designed to suppress the oncogenic alternative splicing event.

Original languageEnglish
Pages (from-to)3975-3984
Number of pages10
JournalCancer Research
Volume70
Issue number10
DOIs
Publication statusPublished - May 15 2010

Fingerprint

Cyclins
Oncogenes
Alleles
Prostatic Neoplasms
Cyclin D1
Alternative Splicing
Neoplasms
RNA Splice Sites
RNA-Binding Proteins
Prostate
Protein Isoforms
Carcinogenesis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Olshavsky, N. A., Comstock, C. E. S., Schiewer, M. J., Augello, M. A., Hyslop, T., Sette, C., ... Knudsen, K. E. (2010). Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Research, 70(10), 3975-3984. https://doi.org/10.1158/0008-5472.CAN-09-3468

Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. / Olshavsky, Nicholas A.; Comstock, Clay E S; Schiewer, Matthew J.; Augello, Michael A.; Hyslop, Terry; Sette, Claudio; Zhang, Jinsong; Parysek, Linda M.; Knudsen, Karen E.

In: Cancer Research, Vol. 70, No. 10, 15.05.2010, p. 3975-3984.

Research output: Contribution to journalArticle

Olshavsky, NA, Comstock, CES, Schiewer, MJ, Augello, MA, Hyslop, T, Sette, C, Zhang, J, Parysek, LM & Knudsen, KE 2010, 'Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene', Cancer Research, vol. 70, no. 10, pp. 3975-3984. https://doi.org/10.1158/0008-5472.CAN-09-3468
Olshavsky, Nicholas A. ; Comstock, Clay E S ; Schiewer, Matthew J. ; Augello, Michael A. ; Hyslop, Terry ; Sette, Claudio ; Zhang, Jinsong ; Parysek, Linda M. ; Knudsen, Karen E. / Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. In: Cancer Research. 2010 ; Vol. 70, No. 10. pp. 3975-3984.
@article{b3fd678dff674815831914d8c23076ba,
title = "Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene",
abstract = "The cyclin D1b oncogene arises from alternative splicing of the CCND1 transcript, and harbors markedly enhanced oncogenic functions not shared by full-length cyclin D1 (cyclin D1a). Recent studies showed that cyclin D1b is selectively induced in a subset of tissues as a function of tumorigenesis; however, the underlying mechanism(s) that control tumor-specific cyclin D1b induction remain unsolved. Here, we identify the RNA-binding protein ASF/SF2 as a critical, allele-specific, disease-relevant effector of cyclin D1b production. Initially, it was observed that SF2 associates with cyclin D1b mRNA (transcript-b) in minigene analyses and with endogenous transcript in prostate cancer (PCa) cells. SF2 association was altered by the CCND1 G/A870 polymorphism, which resides in the splice donor site controlling transcript-b production. This finding was significant, as the A870 allele promotes cyclin D1b in benign prostate tissue, but in primary PCa, cyclin D1b production is independent of A870 status. Data herein provide a basis for this disparity, as tumor-associated induction of SF2 predominantly results in binding to and accumulation of G870-derived transcript-b. Finally, the relevance of SF2 function was established, as SF2 strongly correlated with cyclin D1b (but not cyclin D1a) in human PCa. Together, these studies identify a novel mechanism by which cyclin D1b is induced in cancer, and reveal significant evidence of a factor that cooperates with a risk-associated polymorphism to alter cyclin D1 isoform production. Identification of SF2 as a disease-relevant effector of cyclin D1b provides a basis for future studies designed to suppress the oncogenic alternative splicing event.",
author = "Olshavsky, {Nicholas A.} and Comstock, {Clay E S} and Schiewer, {Matthew J.} and Augello, {Michael A.} and Terry Hyslop and Claudio Sette and Jinsong Zhang and Parysek, {Linda M.} and Knudsen, {Karen E.}",
year = "2010",
month = "5",
day = "15",
doi = "10.1158/0008-5472.CAN-09-3468",
language = "English",
volume = "70",
pages = "3975--3984",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene

AU - Olshavsky, Nicholas A.

AU - Comstock, Clay E S

AU - Schiewer, Matthew J.

AU - Augello, Michael A.

AU - Hyslop, Terry

AU - Sette, Claudio

AU - Zhang, Jinsong

AU - Parysek, Linda M.

AU - Knudsen, Karen E.

PY - 2010/5/15

Y1 - 2010/5/15

N2 - The cyclin D1b oncogene arises from alternative splicing of the CCND1 transcript, and harbors markedly enhanced oncogenic functions not shared by full-length cyclin D1 (cyclin D1a). Recent studies showed that cyclin D1b is selectively induced in a subset of tissues as a function of tumorigenesis; however, the underlying mechanism(s) that control tumor-specific cyclin D1b induction remain unsolved. Here, we identify the RNA-binding protein ASF/SF2 as a critical, allele-specific, disease-relevant effector of cyclin D1b production. Initially, it was observed that SF2 associates with cyclin D1b mRNA (transcript-b) in minigene analyses and with endogenous transcript in prostate cancer (PCa) cells. SF2 association was altered by the CCND1 G/A870 polymorphism, which resides in the splice donor site controlling transcript-b production. This finding was significant, as the A870 allele promotes cyclin D1b in benign prostate tissue, but in primary PCa, cyclin D1b production is independent of A870 status. Data herein provide a basis for this disparity, as tumor-associated induction of SF2 predominantly results in binding to and accumulation of G870-derived transcript-b. Finally, the relevance of SF2 function was established, as SF2 strongly correlated with cyclin D1b (but not cyclin D1a) in human PCa. Together, these studies identify a novel mechanism by which cyclin D1b is induced in cancer, and reveal significant evidence of a factor that cooperates with a risk-associated polymorphism to alter cyclin D1 isoform production. Identification of SF2 as a disease-relevant effector of cyclin D1b provides a basis for future studies designed to suppress the oncogenic alternative splicing event.

AB - The cyclin D1b oncogene arises from alternative splicing of the CCND1 transcript, and harbors markedly enhanced oncogenic functions not shared by full-length cyclin D1 (cyclin D1a). Recent studies showed that cyclin D1b is selectively induced in a subset of tissues as a function of tumorigenesis; however, the underlying mechanism(s) that control tumor-specific cyclin D1b induction remain unsolved. Here, we identify the RNA-binding protein ASF/SF2 as a critical, allele-specific, disease-relevant effector of cyclin D1b production. Initially, it was observed that SF2 associates with cyclin D1b mRNA (transcript-b) in minigene analyses and with endogenous transcript in prostate cancer (PCa) cells. SF2 association was altered by the CCND1 G/A870 polymorphism, which resides in the splice donor site controlling transcript-b production. This finding was significant, as the A870 allele promotes cyclin D1b in benign prostate tissue, but in primary PCa, cyclin D1b production is independent of A870 status. Data herein provide a basis for this disparity, as tumor-associated induction of SF2 predominantly results in binding to and accumulation of G870-derived transcript-b. Finally, the relevance of SF2 function was established, as SF2 strongly correlated with cyclin D1b (but not cyclin D1a) in human PCa. Together, these studies identify a novel mechanism by which cyclin D1b is induced in cancer, and reveal significant evidence of a factor that cooperates with a risk-associated polymorphism to alter cyclin D1 isoform production. Identification of SF2 as a disease-relevant effector of cyclin D1b provides a basis for future studies designed to suppress the oncogenic alternative splicing event.

UR - http://www.scopus.com/inward/record.url?scp=77952796886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952796886&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-3468

DO - 10.1158/0008-5472.CAN-09-3468

M3 - Article

C2 - 20460515

AN - SCOPUS:77952796886

VL - 70

SP - 3975

EP - 3984

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 10

ER -